Aclaris therapeutics reports first quarter 2023 financial results and provides a corporate update

- management to host conference call at 8:00 am et today – wayne, pa., may 08, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update.
ACRS Ratings Summary
ACRS Quant Ranking